Steve McCune

518 total citations
16 papers, 326 citations indexed

About

Steve McCune is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Steve McCune has authored 16 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Steve McCune's work include Advanced Breast Cancer Therapies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (3 papers). Steve McCune is often cited by papers focused on Advanced Breast Cancer Therapies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (3 papers). Steve McCune collaborates with scholars based in United States, Germany and United Kingdom. Steve McCune's co-authors include T M Townes, Toshio Asakura, Muredach P. Reilly, Bruce W. Hollis, R U Simpson, JT Prchal, JF Prchal, Katarzyna J. Jerzak, M. Harada and Timothy R. Wilson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Steve McCune

16 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steve McCune United States 10 169 157 85 79 55 16 326
Jennifer Foglietta Italy 10 162 1.0× 283 1.8× 108 1.3× 65 0.8× 36 0.7× 20 413
Tristan Maurina France 10 154 0.9× 108 0.7× 118 1.4× 73 0.9× 18 0.3× 30 293
Ankit Patel United States 11 79 0.5× 85 0.5× 99 1.2× 72 0.9× 17 0.3× 26 285
Stephen Chanock United States 8 53 0.3× 76 0.5× 135 1.6× 58 0.7× 25 0.5× 10 266
Meiling Zhu China 14 156 0.9× 137 0.9× 199 2.3× 92 1.2× 10 0.2× 25 410
Carina Forsare Sweden 10 76 0.4× 139 0.9× 89 1.0× 111 1.4× 22 0.4× 14 272
Lubna N. Chaudhary United States 10 56 0.3× 183 1.2× 84 1.0× 148 1.9× 12 0.2× 33 346
Jérôme Alexandre France 3 174 1.0× 139 0.9× 296 3.5× 78 1.0× 47 0.9× 4 445
Arya Mariam Roy United States 10 87 0.5× 170 1.1× 114 1.3× 79 1.0× 18 0.3× 74 355
Frank Richard Germany 9 105 0.6× 52 0.3× 116 1.4× 77 1.0× 68 1.2× 17 372

Countries citing papers authored by Steve McCune

Since Specialization
Citations

This map shows the geographic impact of Steve McCune's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve McCune with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve McCune more than expected).

Fields of papers citing papers by Steve McCune

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve McCune. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve McCune. The network helps show where Steve McCune may publish in the future.

Co-authorship network of co-authors of Steve McCune

This figure shows the co-authorship network connecting the top 25 collaborators of Steve McCune. A scholar is included among the top collaborators of Steve McCune based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve McCune. Steve McCune is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
3.
4.
Tripathy, Debu, Gabrielle B. Rocque, Joanne L. Blum, et al.. (2022). 251P Real-world clinical outcomes of palbociclib plus endocrine therapy (ET) in hormone receptor–positive advanced breast cancer: Results from the POLARIS trial. Annals of Oncology. 33. S651–S652. 5 indexed citations
5.
Lindeman, Geoffrey J., Tharu M. Fernando, Rebecca Bowen, et al.. (2022). VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results. Clinical Cancer Research. 28(15). 3256–3267. 49 indexed citations
6.
Felip, Enriqueta, Martin Reck, Rüediger Liersch, et al.. (2022). 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC). Immuno-Oncology Technology. 16. 100106–100106. 13 indexed citations
7.
Zhou, C., Meghna Das Thakur, Manoj Srivastava, et al.. (2021). 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology. 32. S1374–S1374. 41 indexed citations
8.
Petrylak, Daniel P., José Luis Perez‐Gracia, Louis Lacombe, et al.. (2021). 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 32. S629–S630. 11 indexed citations
9.
McCune, Steve, Leora Horn, Ivor Percent, et al.. (2019). EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. Journal of Thoracic Oncology. 14(10). S1018–S1019. 1 indexed citations
10.
Karuturi, Meghan, Joanne L. Blum, John M. Wallmark, et al.. (2019). Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS. Annals of Oncology. 30. v133–v133. 4 indexed citations
11.
Motzer, Robert J., Chung‐Han Lee, Hamid Emamekhoo, et al.. (2019). ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). Annals of Oncology. 30. v889–v890. 22 indexed citations
12.
Chau, Ian, Georg Martin Haag, Osama E. Rahma, et al.. (2018). MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. Annals of Oncology. 29. viii439–viii440. 14 indexed citations
13.
14.
McCune, Steve, et al.. (2009). Vitamin D deficiency in the spontaneously hypertensive heart failure [SHHF] prone rat. Nutrition Metabolism and Cardiovascular Diseases. 20(9). 641–646. 34 indexed citations
15.
McCune, Steve, et al.. (1996). Stable transduction of recombinant adeno-associated virus into hematopoietic stem cells from normal and sickle cell patients.. PubMed. 2(1). 24–30. 23 indexed citations
16.
McCune, Steve, et al.. (1994). Recombinant human hemoglobins designed for gene therapy of sickle cell disease.. Proceedings of the National Academy of Sciences. 91(21). 9852–9856. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Foglietta Breakdown of academic impact, for papers by Tristan Maurina Breakdown of academic impact, for papers by Ankit Patel Breakdown of academic impact, for papers by Stephen Chanock Breakdown of academic impact, for papers by Meiling Zhu Breakdown of academic impact, for papers by Carina Forsare Breakdown of academic impact, for papers by Lubna N. Chaudhary Breakdown of academic impact, for papers by Jérôme Alexandre Breakdown of academic impact, for papers by Arya Mariam Roy Breakdown of academic impact, for papers by Frank Richard
Rankless by CCL
2026